|
1
|
Ginsberg RJ, Kris K and Armstrong G:
Cancer of the lung. Principles and Practice of Oncology. 4th
edition. Lippincott; Philadelphia: pp. 673–682. 1993
|
|
2
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sasaki H, Endo K, Konishi A, et al: EGFR
mutation status in Japanese lung cancer patients: genotyping
analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sasaki H, Shimizu S, Endo K, et al: EGFR
and erbB2 mutation status in Japanese lung cancer patients. Int J
Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fukuoka M, Wy YL, Thongprasert S, et al:
Biomarker analyses and first overall survival results from a phase
III, randomized, open-label, first-line study of gefitinib versus
carboplatin/paclitaxel in clinically selected patients with
advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol.
29:2866–2874. 2011. View Article : Google Scholar
|
|
7
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hammerman PS, Sos ML, Ramos AH, et al:
Mutations in the DDR2 kinase gene identify a novel therapeutic
target in squamous cell lung cancer. Cancer Discovery. 1:78–89.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vogel WF, Abdulhussein R and Ford CE:
Sensing extracellular matrix: an update on discoidin domain
receptor function. Cell Signal. 18:1108–1116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ford CE, Lau SK, Zhu CQ, et al: Expression
and mutation analysis of the discoidin domain receptors 1 and 2 in
non-small cell lung carcinoma. Br J Cancer. 96:808–814. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Davies H, Hunter C, Smith R, et al:
Somatic mutations of the protein kinase gene family in human lung
cancer. Cancer Res. 65:7591–7595. 2005.PubMed/NCBI
|
|
12
|
Johnson JD, Edman JC and Rutter WJ: A
receptor tyrosine kinase found in breast carcinoma cell has an
extracellular discoidin I-like domain. Proc Natl Acad Sci USA.
90:5677–5681. 1993. View Article : Google Scholar
|
|
13
|
Alves F, Vogel W, Mossie K, et al:
Distinct structural characteristics of discoidin I subfamily
receptor tyrosine kinases and complementary expression in human
cancer. Oncogene. 10:609–618. 1995.
|
|
14
|
Barker KT, Martindale JE, Mitchell PJ, et
al: Expression patterns of the novel receptor-like tyrosine kinase,
DDR, in human breast tumors. Oncogene. 10:569–575. 1995.PubMed/NCBI
|
|
15
|
Nemoto T, Ohashi K, Akashi T, et al:
Overexpression of protein tyrosine kinases in human esophageal
cancer. Pathobiology. 65:195–203. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vogel W, Gish GD, Alves F, et al: The
discoidin domain receptor tyrosine kinases are activated by
collagen. Mol Cell. 1:13–23. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Olaso E, Labrador JP, Wang L, et al:
Discoidin domain receptor 2 regulates fibroblast proliferation and
migration through the extracellular matrix in association with
transcriptional activation of matrix metalloproteinase-2. J Biol
Chem. 277:3606–3613. 2002. View Article : Google Scholar
|
|
18
|
Olaso E, Ikeda K, Eng FJ, et al: DDR2
receptor promotes MMP-2-mediated proliferation and invasion by
hepatic stellate cells. J Clin Invest. 108:1369–1378. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu L, Peng H, Wu D, et al: Activation of
the discoidin domain receptor 2 induces expression of matrix
metalloproteinase 13 associated with osteoarthritis in mice. J Biol
Chem. 280:548–555. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Badiola I, Villacé P, Basaldua I, et al:
Downregulation of discoidin domain receptor 2 in A375 human
melanoma cells reduces its experimental liver metastasis ability.
Oncol Rep. 26:971–978. 2011.PubMed/NCBI
|
|
21
|
Day E, Waters B, Spiegel K, et al:
Inhibition of collagen-induced discoidin domain receptor 1 and 2
activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol.
599:44–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bantscheff M, Eberhard D, Abraham Y, et
al: Quantitative chemical proteomics reveals mechanisms of action
of clinical ABL kinase inhibitors. Nat Biotech. 25:1035–1044. 2007.
View Article : Google Scholar : PubMed/NCBI
|
